Import Bevatas 100mg to New York | PRIMECARE IMPEX Cold-Chain Supply

Bevatas 100mg Injection (Bevacizumab): The Complete B2B Procurement & Export Guide

Are you searching for a certified, high-capacity bulk supplier of Bevatas 100mg Injection? PRIMECARE IMPEX is an industry-leading pharmaceutical exporter from India, specializing in the temperature-controlled distribution of advanced oncology and biosimilar treatments. We offer highly optimized supply chain services directly to healthcare networks, wholesalers, and medical institutions across New York (USA), Bristol (UK), Sydney (Australia), and Riyadh (Saudi Arabia).

Primary Clinical Indications

• Metastatic Colorectal Cancer (mCRC): Used in combination with intravenous 5-fluorouracil-based chemotherapy.

• Non-Small Cell Lung Cancer (NSCLC): First-line therapy for unresectable, advanced, or metastatic non-squamous variants.

• Glioblastoma Multiforme: Indicated for recurrent brain tumors showing progression following prior therapy.

• Metastatic Renal Cell Carcinoma (mRCC): Utilized alongside interferon-alfa therapies.

• Advanced Gynecological Malignancies: Including persistent, recurrent, or metastatic cervical cancer, epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

In-Depth Technical Product Information

1. Mechanism of Action

Bevatas 100mg works via highly targeted angiogenesis inhibition. The active compound, Bevacizumab, selectively binds to the Vascular Endothelial Growth Factor (VEGF-A) protein. By neutralizing this key endothelial ligand, the drug stops it from interacting with its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells.

This specific blocking action prevents the proliferation, signaling, and formation of new blood vessels (neo-vascularization) toward the tumor mass. Deprived of oxygen, glucose, and essential systemic nutrients, the vascular structure of the tumor regresses, effectively halting tumor growth and optimizing the delivery of co-administered cytotoxic chemotherapies.

2. Temperature-Controlled Storage and Safe Handling

• Cold-Chain Maintenance: Must be stored continuously in a secure pharmaceutical refrigerator maintained strictly between 2°C to 8°C (36°F to 46°F).

• Physical Protection: Do not freeze or shake the vial under any circumstances, as severe agitation can denature the monoclonal antibody proteins. Store in the original outer commercial carton to protect the liquid formulation from direct light exposure.

• Preparation Safety: The solution does not contain any antimicrobial preservatives. Reconstitution, dilution, and administrative preparation should be completed using aseptic techniques by trained clinical personnel.

3. Secondary Effects & Clinical Risk Assessment

While a highly effective monoclonal antibody, Bevatas 100mg requires close clinical monitoring due to a distinct profile of manageable and severe adverse effects:

• Cardiovascular and Renal: Arterial hypertension (frequently observed, requiring blood pressure monitoring) and proteinuria (excess protein in the urine).

• Hematologic Challenges: Enhanced susceptibility to systemic bleeding events (including epistaxis and gastrointestinal hemorrhages) and a higher risk of arterial thromboembolic events.

• Gastrointestinal Perforations: A serious, less frequent complication presenting as abdominal pain, requiring immediate clinical assessment.

• Surgical Warning: Bevacizumab alters physiological wound-healing mechanisms. It must not be administered within 28 days before or after any major elective surgery or extensive dental surgical procedures.

4. Core Commercial Advantages of Bevatas 100mg

• Broad-Spectrum Multi-Indication Efficacy: Demonstrates versatility across gastrointestinal, pulmonary, neurological, and gynecological cancers.

• Synergistic Formulation: Significantly amplifies the tumor-shrinking capabilities of traditional cytotoxic agents when used in combination protocols.

• Cost-Efficient Generic Quality: Manufactured by Intas Pharmaceuticals, it offers a premium, globally trusted biosimilar alternative to high-cost innovator brands, providing strong cost advantages for wholesale buyers.

5. Strict Export Documentation & Logistics Standards

As an established exporter from India, PRIMECARE IMPEX ensures complete cross-border regulatory compliance by providing all essential validation documents with every shipment:

• Authentic Certificate of Analysis (COA) & batch-specific technical release documentation.

• Validated WHO-GMP Compliant Sourcing and localized product safety parameters.

• Country of Origin Certification alongside full commercial invoicing and localized packing indices.

• Active Cold-Chain Logistics Management: Utilizing advanced temperature-monitored air freight containers to guarantee that the 2°C to 8°C threshold remains unbroken from our facility to destination ports.

• B2B Trade Disclaimer: Bevatas 100mg (Bevacizumab) Injection is classified as a hazardous anti-cancer prescription medicine and must be prepared and administered exclusively by qualified medical specialists within a controlled clinical environment. The informational content compiled here serves solely as a high-level B2B trade resource and digital catalog for commercial procurement agents. It is not intended as individual medical advice or a substitute for expert oncological diagnosis and patient management.

📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India

[GROUP OF PRIME CARE IMPEX PVT. LTD.]

Your Integrated B2B Hub for Bulk Oncology Supply and Validated Global Distribution.

• 🌐 Website: www.medicineexporterfromindia.com

• 📧 Email: exports@ernestpharmaceuticals.com

• 📦 Business Type: Exporter | Bulk Supplier | Distributor

• 📲 WhatsApp: +91 9673008130

• 🔗 Instant Connection: Click Here to Chat on WhatsApp